Summary Survival and prognostic factors were analysed in 150 patients with histologically confirmed epithelial ovarian cancer stage IA-IIA. The relapse-free and overall survival rates were, respectively, 81 % and 88% after 3 and 74% and 84% after 5 al, 1996). Other studies, however, did not confirm these indications (Dembo et al, 1986 (Dembo et al, , 1990 Kaplan-Meier and compared using the log-rank test. The Cox model (Cox, 1972) was fitted to the data after graphical check of proportional hazards assumption to evaluate the prognostic value of considered factors, taking into account the potential reciprocal confounding effect.
Few studies have been conducted on prognostic factors in earlystage (I-IIA) ovarian cancer. Some authors have suggested that age, tumour grade, stage and rupture of the tumour capsule have a relevant impact on the survival of early ovarian cancer patients (Webb et al, 1973; Einhom et al, 1985) . A recent study including 194 patients with stage I ovarian cancer identified grade, presence of ascites and surface tumour as independent prognostic factors (Ahmed et al, 1996) . Other studies, however, did not confirm these indications (Dembo et al, 1986 (Dembo et al, , 1990 Kaplan-Meier and compared using the log-rank test. The Cox model (Cox, 1972) was fitted to the data after graphical check of proportional hazards assumption to evaluate the prognostic value of considered factors, taking into account the potential reciprocal confounding effect.
At the time of the study analysis, 39 women had relapsed and 29 had died (27 out of the 39 who relapsed and 2 out of Ill with no recurrence of disease for causes unrelated to ovarian cancer).
The relapse-free and overall survival rates were, respectively, 81% and 88% after 3 years and 74% and 84% after 5 years.
Patients 53 years old or less tended to have a better 5-year survival rate (88%) than the older ones (79%; log-rank test P = 0.04, multivariate analysis P = 0.07). Women with clear-cell and undifferentiated tumour type had a 5-year survival of 66% compared with 88% for women with other histological types (log-rank test P = 0.002), but this difference was not significant in the multivariate analysis (P = 0.59). Tumour grade 3 had a 69% 5-year survival rate, compared with 91% for grade 1-2 (log-rank test P = 0.0004; multivariate analysis, P = 0.04).
Compared with patients with stage IC, there was a significant difference in survival after 5 years between women with presence of tumour with or without ascites on the surface of the ovary (88%) or intraoperative rupture of the tumour capsule (72%) (data not shown in Table, multivariate analysis P = 0.03).
The site of relapse was the pelvis and/or the vaginal cuff in 16 (41%) cases and extrapelvic in 23 (59%) cases. No relationship emerged between site of relapse and age, histotype, grade, stage and tumour volume at first surgery.
Out of 39 patients with recurrent disease, 24 were treated with chemotherapy alone, eight with chemotherapy plus surgery and/or radiotherapy and three with radiotherapy alone; four patients had no treatment. The response to treatment at relapse was 'complete' in 11 patients (six out of the 16 patients with pelvic and/or vaginal cuff relapse and five out of the 23 patients with extrapelvic relapse), 'partial' in seven 'no change' in seven and ten cases progressed. Patients with recurrent disease had a 47% 3-year survival rate after relapse.
DISCUSSION
The results of this study show that the prognosis of patients with early-stage ovarian cancer is favourable. This finding is consistent with previous published studies that showed 5-year survival rates raging from 75% to 90% (Webb et al, 1973; Einhorn et al, 1985; Sevelda et al, 1989; Dembo et al, 1990; Lund & Williamson, 1991; Shueler et al, 1993; Ahmed et al, 1996) . The analysis of various prognostic factors indicates as main factor the grade differentiation of the tumour. This finding is consistent with the results of previous studies (Webb et al, 1973; Sevelda et al, 1989; Ahmed et al, 1996) . Thus, tumour grading is the main factor in the identification of patients with early ovarian cancer who could benefit from adjuvant chemotherapy.
